X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3789) 3789
Newsletter (498) 498
Publication (340) 340
Book Review (26) 26
Book Chapter (9) 9
Conference Proceeding (5) 5
Newspaper Article (5) 5
Dissertation (4) 4
Magazine Article (4) 4
Government Document (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3282) 3282
male (2972) 2972
prostate-specific antigen (2244) 2244
prostate cancer (2225) 2225
index medicus (1588) 1588
prostate-specific antigen - blood (1512) 1512
aged (1408) 1408
middle aged (1402) 1402
cancer (1366) 1366
prostatic neoplasms - immunology (1310) 1310
oncology (1165) 1165
prostatic neoplasms - pathology (1063) 1063
prostatic neoplasms - diagnosis (775) 775
urology & nephrology (757) 757
research (744) 744
prostate (628) 628
prostate-specific antigen - immunology (566) 566
diagnosis (553) 553
aged, 80 and over (526) 526
prostatic neoplasms - blood (523) 523
animals (490) 490
analysis (457) 457
biomarkers, tumor - blood (444) 444
antigens (437) 437
prognosis (436) 436
prostatic neoplasms - therapy (416) 416
adult (411) 411
radical prostatectomy (411) 411
prostatic neoplasms - surgery (380) 380
men (378) 378
care and treatment (374) 374
treatment outcome (371) 371
biopsy (370) 370
neoplasm staging (359) 359
antigen (349) 349
immunology (347) 347
prostate-specific antigen - analysis (343) 343
carcinoma (336) 336
prostatectomy (327) 327
female (325) 325
risk factors (324) 324
retrospective studies (318) 318
psa (312) 312
mice (308) 308
predictive value of tests (308) 308
sensitivity and specificity (303) 303
expression (301) 301
urology (299) 299
tumors (298) 298
prostatic neoplasms - drug therapy (289) 289
endocrinology & metabolism (279) 279
oncology, experimental (275) 275
health aspects (273) 273
prostate-specific antigen - metabolism (273) 273
immunohistochemistry (269) 269
proteins (265) 265
medicine (259) 259
prostate - pathology (257) 257
prostatic neoplasms - metabolism (257) 257
risk (247) 247
immunotherapy (246) 246
medicine & public health (243) 243
adenocarcinoma (242) 242
metastasis (241) 241
serum (241) 241
article (238) 238
prostatic neoplasms - genetics (232) 232
cell line, tumor (227) 227
surgery (227) 227
prostatic neoplasms - mortality (224) 224
research article (224) 224
biomarkers (222) 222
time factors (215) 215
prostate-specific antigen - genetics (214) 214
survival (210) 210
patients (208) 208
multidisciplinary sciences (207) 207
antigens, neoplasm - analysis (201) 201
mortality (201) 201
science (193) 193
medical research (187) 187
nephrology (187) 187
disease progression (182) 182
therapy (181) 181
follow-up studies (180) 180
pathology (180) 180
reports (178) 178
adenocarcinoma - immunology (177) 177
immunoassay (177) 177
progression (173) 173
neoplasm grading (169) 169
usage (168) 168
enzyme-linked immunosorbent assay (166) 166
disease-free survival (165) 165
cells (163) 163
prostate - immunology (161) 161
prostatic neoplasms - prevention & control (161) 161
prostatic neoplasms - epidemiology (160) 160
prostatic neoplasms - radiotherapy (158) 158
antibodies (154) 154
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4083) 4083
French (47) 47
Japanese (44) 44
Russian (25) 25
Chinese (21) 21
German (18) 18
Spanish (18) 18
Hungarian (14) 14
Norwegian (13) 13
Italian (10) 10
Swedish (4) 4
Danish (2) 2
Dutch (2) 2
Hebrew (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Oncotarget, ISSN 1949-2553, 08/2016, Volume 7, Issue 33, pp. 52810 - 52817
While programmed cell death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in several solid tumors, prior results in men with metastatic castration... 
Immune response | Immunotherapy | Immunology and Microbiology Section | Enzalutamide | Immunity | PD-1 | Prostate cancer | DOCETAXEL | INFILTRATION | CELL BIOLOGY | CELL LUNG-CANCER | prostate cancer | PEMBROLIZUMAB | MELANOMA | immunotherapy | PD-L1 | NIVOLUMAB | enzalutamide | IPILIMUMAB | ANTIGEN | Phenylthiohydantoin - adverse effects | Hypothyroidism - chemically induced | Humans | Middle Aged | Prostatic Neoplasms, Castration-Resistant - immunology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Myositis - chemically induced | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Hypothyroidism - immunology | Myositis - immunology | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Aged, 80 and over | Prostatic Neoplasms, Castration-Resistant - prevention & control | Prostate-Specific Antigen - metabolism | Antibodies, Monoclonal, Humanized - adverse effects | Phenylthiohydantoin - immunology | Drug Administration Schedule | Programmed Cell Death 1 Receptor - metabolism | Antineoplastic Combined Chemotherapy Protocols - immunology | Prostatic Neoplasms, Castration-Resistant - metabolism | Remission Induction | Phenylthiohydantoin - analogs & derivatives | Phenylthiohydantoin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Prostate-Specific Antigen - immunology | Antibodies, Monoclonal, Humanized - immunology | Drug Resistance, Neoplasm - drug effects
Journal Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 08/2011, Volume 71, Issue 15, pp. 5235 - 5244
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 08/2013, Volume 133, Issue 3, pp. 624 - 636
Journal Article